From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.
- 1Brigham and Women's Hospital, Harvard Medical School, ARCND, 60 Fenwood Rd, Boston, MA, 02115, USA. [email protected].
- 2Brigham and Women's Hospital, Harvard Medical School, ARCND, 60 Fenwood Rd, Boston, MA, 02115, USA.
Abstract
A major challenge for identifying a disease-modifying cure for Parkinson's disease (PD) is creating models resembling key features of the disease including resting tremor, bradykinesia, muscle rigidity and gait disturbances. In addition, PD patients often develop cognitive symptoms that are associated with pathology in neocortical areas. Initially, PD rodent models were generated primarily by chemical neurotoxins that induce an acute loss of dopaminergic neurons. Upon discovery of familial-PD-linked genetic mutations in the SNCA gene-encoding α-synuclein (αS)-mice carrying these mutations provided deeper insight into the pathologic role of this synaptic protein throughout the brain. αS transgenic mouse models stand out for their ability to develop intraneuronal lesions that are rich in αS phospho-serine 129, a histopathological signature of the human PD brain. Recent advances in αS protein biochemistry led to the generation of mice carrying strategic amplifications of familial-PD-linked αS mutants, resulting in more pronounced neurodegeneration and progressive phenotype development. Here we review advances of αS transgenic mouse model development with a focus on strategic mutations that may have greater potential for identifying underlying disease mechanisms than classical single-mutant and wild-type αS overexpressing mice. We also present how the mice are currently used in testing drug efficacy and target engagement for PD drug discovery and outline strategies for utilizing such mice in basic and translational research.
Related
- Regulatory endorsement for the application of α-synuclein seed amplification assay as a susceptibility and risk biomarker for clinical trials targeting synucleinopathies
- Cerebrospinal fluid alpha-synuclein seed amplification assay positivity identifies a prognostically distinct subgroup in amyotrophic lateral sclerosis
- Sexually transmitted infection syndemic interactions: Biological amplification between HIV, HSV-2, syphilis, and HPV and implications for co-treatment strategies
- Development of a Pelvic Finite Element Model for Future Assessment of Fixation Strategies in Both-Column Acetabular Fractures
- Pulmonary inflammation in severe pneumonia is characterised by compartmentalised and mechanistically distinct sub-phenotypes
BibTeX
@article{nuber2026from,
title = {{From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.}},
author = {Silke Nuber and Saranna Fanning and Ulf Dettmer},
journal = {Acta neuropathologica},
year = {2026},
month = oct,
doi = {10.1007/s00401-026-03112-4},
url = {https://europepmc.org/article/MED/42961519},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - From dosage alteration to amplification strategies: mechanistically defined alpha-synuclein mouse models for Parkinson's disease therapy development.
AU - Silke Nuber
AU - Saranna Fanning
AU - Ulf Dettmer
PY - 2026
DA - 2026/10/30
JO - Acta neuropathologica
DO - 10.1007/s00401-026-03112-4
UR - https://europepmc.org/article/MED/42961519
AB - A major challenge for identifying a disease-modifying cure for Parkinson's disease (PD) is creating models resembling key features of the disease including resting tremor, bradykinesia, muscle rigidity and gait disturbances. In addition, PD patients often develop cognitive symptoms that are associated with pathology in neocortical areas. Initially, PD rodent models were generated primarily by chemical neurotoxins that induce an acute loss of dopaminergic neurons. Upon discovery of familial-PD-linked genetic mutations in the SNCA gene-encoding α-synuclein (αS)-mice carrying these mutations provided deeper insight into the pathologic role of this synaptic protein throughout the brain. αS transgenic mouse models stand out for their ability to develop intraneuronal lesions that are rich in αS phospho-serine 129, a histopathological signature of the human PD brain. Recent advances in αS protein biochemistry led to the generation of mice carrying strategic amplifications of familial-PD-linked αS mutants, resulting in more pronounced neurodegeneration and progressive phenotype development. Here we review advances of αS transgenic mouse model development with a focus on strategic mutations that may have greater potential for identifying underlying disease mechanisms than classical single-mutant and wild-type αS overexpressing mice. We also present how the mice are currently used in testing drug efficacy and target engagement for PD drug discovery and outline strategies for utilizing such mice in basic and translational research.
SN - 0001-6322
SN - 1432-0533
ER -